Algenomics, a company specializing in the development of RNA-based gene therapies, announced on July 6 that CEO Sungwook Lee has been invited to speak at both the RNA Society and a global bio conference, where he will present the company’s proprietary RNA editing platform technology and clinical development strategy.

Algenomics CEO Sungwook Lee Invited as Speaker at RNA Symposium and Global Bio Conference View original image

First, CEO Lee will deliver a presentation at the Summer Symposium of the RNA Division of the Korean Society for Molecular and Cellular Biology (KSMCB) on July 7, 2026. He will introduce the design and optimization process of trans-splicing ribozymes, as well as how the company developed therapeutic candidates based on this platform technology. In particular, he plans to share with the academic community the regulatory approval process and clinical development strategy for the anti-cancer gene therapy 'RZ-001 (Taspitimagen advec),' which targets cancer types with high unmet medical needs.


Subsequently, on August 10, CEO Lee will serve as an invited speaker at the global bio conference "Bio China Global Forum Korea." In this presentation, he is expected to share Algenomics’ RNA trans-splicing ribozyme platform and circular RNA platform commercialization strategies, as well as the latest clinical and business development achievements, with global pharmaceutical companies and investors.


Algenomics is developing gene therapies that not only precisely cleave disease-causing target RNAs using its proprietary RNA trans-splicing ribozyme platform, but also ligate therapeutic RNAs to fundamentally treat the root causes of diseases. Its lead pipeline, 'RZ-001,' demonstrated its regulatory science potential by obtaining RMAT (Regenerative Medicine Advanced Therapy) designation from the U.S. Food and Drug Administration (FDA) based on safety and early efficacy data presented at the American Association for Cancer Research (AACR) in April.



CEO Sungwook Lee stated, "We are pleased to have the opportunity to showcase Algenomics’ technology and development status at prestigious academic and business platforms both domestically and internationally. We will introduce the scientific basis of our RNA trans-splicing ribozyme platform and innovative new drug development strategies to the academic community, while using this opportunity to accelerate business discussions with pharmaceutical and biotech companies on the global stage."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing